ストックスクリーナーアプリを入手
1.16
4.17%
-0.04
アフターアワーズ：
1.17
0.01
+0.86%
前日終値:
$1.20
開ける：
$1.2
24時間の取引高:
1.04M
Relative Volume:
1.04
時価総額：
$179.22M
収益：
$46.88M
当期純損益:
$-172.66M
株価収益率:
-0.9309
EPS:
-1.2461
ネットキャッシュフロー:
$-170.57M
1週間 パフォーマンス:
-7.26%
1か月 パフォーマンス:
-17.86%
6か月 パフォーマンス:
-28.57%
1年 パフォーマンス:
+9.52%
1日の値動き範囲:
$1.13
$1.2001
1週間の範囲:
$1.13
$1.2599
52週間の値動き範囲:
$1.03
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
名前
Coherus Oncology Inc
セクター
電話
(650) 649-3530
住所
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.16 | 185.40M | 46.88M | -172.66M | -170.57M | -1.2461 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-23 | 開始されました | Oppenheimer | Outperform |
| 2025-09-04 | アップグレード | Maxim Group | Hold → Buy |
| 2024-08-16 | ダウングレード | UBS | Buy → Neutral |
| 2023-11-17 | 開始されました | Robert W. Baird | Outperform |
| 2023-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2023-07-24 | 開始されました | Citigroup | Buy |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2023-03-28 | アップグレード | UBS | Neutral → Buy |
| 2022-06-14 | 開始されました | UBS | Neutral |
| 2022-03-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 開始されました | BofA Securities | Neutral |
| 2020-04-17 | 開始されました | SunTrust | Buy |
| 2019-08-13 | 開始されました | Mizuho | Buy |
| 2019-08-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-08-02 | 繰り返されました | Maxim Group | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-07 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-28 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-09 | 繰り返されました | Maxim Group | Buy |
| 2017-08-08 | 繰り返されました | JP Morgan | Overweight |
| 2017-06-13 | 繰り返されました | Maxim Group | Buy |
| 2017-05-05 | 開始されました | BMO Capital Markets | Outperform |
| 2016-10-19 | 開始されました | Robert W. Baird | Outperform |
| 2016-09-07 | 開始されました | Maxim Group | Buy |
| 2016-07-27 | 開始されました | Citigroup | Buy |
| 2016-01-20 | 開始されました | Credit Suisse | Outperform |
すべてを表示
Coherus Oncology Inc (CHRS) 最新ニュース
Q3 EPS Estimates for Coherus Oncology Cut by HC Wainwright - marketbeat.com
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript - The Globe and Mail
ETFs Investing in Coherus Oncology, Inc. Stocks - TradingView
CHRS Maintained by Guggenheim -- Price Target Lowered to $10.00 - GuruFocus
Coherus Oncology Is Maintained at Buy by Guggenheim - Moomoo
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria
Coherus Oncology Price Target Cut to $10.00/Share From $12.00 by Guggenheim - Moomoo
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Value ETF - dars.gov.et
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ... - finance.yahoo.com
Coherus Oncology, Inc. 2026 Q2 10-Q Highlights: Financials, Risks, and Forward-Looking Statements for Investors - Minichart
Coherus Oncology Q2 2026 Results: LOQTORZI Revenue Growth, Pipeline Progress, and Financial Update - Minichart
CHRS Looks 83.5% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Q2 Earnings Call Highlights - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results - MarketBeat
CHRS: LOQTORZI sales rose 15% in Q2, with key clinical data readouts expected later in 2026 - TradingView
Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Coherus Oncology Inc (CHRS) Worth the Investment After Q2 Ear - GuruFocus
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology (NASDAQ: CHRS) posts Q2 2026 loss amid growing LOQTORZI revenue - Stock Titan
Coherus Oncology: Q2 Earnings Snapshot - Barchart.com
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update - manilatimes.net
Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates - TradingView
Coherus Oncology Q2 Revenue Rises To $14.3 Million - Quiver Quantitative
CHRS: Q2 2026 revenue up 39% year-over-year, net loss narrows, and pipeline advances continue - TradingView
BRIEF-Coherus Oncology Q2 Net Income USD -20.631 Million - TradingView
Coherus projects October data disclosure as cancer trials mature - Stock Titan
CHRS Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Coherus Oncology Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Coherus Oncology: The Catalyst Rich Period Is Here (NASDAQ:CHRS) - Seeking Alpha
Lobbying Update: $95,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
BlackRock (CHRS holder) discloses 8.93M Coherus Oncology shares under sole control - Stock Titan
CHRS|Coherus BioSciences Inc|Price:1.210|Chg%:-0.030 - TradingKey
Coherus Oncology Market Sentiment - Benzinga España
CHRS|Coherus BioSciences Inc|Price:1.410|Chg%:-0.020 - TradingKey
Coherus BioSciences stock trades lower as revenue pressure and patent loss reshape outlook - Ad-hoc-news.de
CHRS Q2'26 Earnings: revenue estimate is 14.41M USD - TradingView
Coherus Oncology to report Q2 2026 financial results on August 5 - scanx.trade
Coherus BioSciences stock trades around recent lows as revenue declines and oncology pivot continues - Ad-hoc-news.de
Coherus Oncology Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Coherus to webcast second-quarter results Aug. 5 at 5 p.m. - Stock Titan
Q3 2025 Coherus Oncology Inc Earnings Call Transcript - GuruFocus
Coherus Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Lanfear Dennis M - Moomoo
CHRS Q1 2026 Earnings: Narrowed Loss Exceeds ExpectationsEarnings Preview - dars.gov.et
Coherus BioSciences stock stays supported by oncology focus - AD HOC NEWS
Coherus Oncology (CHRS) The Citizens JMP Life Sciences Conference 2025 Summary - Quartr
Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing - Ad-hoc-news.de
CHRS Stock Price, Quote & Chart - ChartMill
Coherus Oncology Inc (CHRS) 財務データ
収益
当期純利益
現金流量
EPS
2.20%
0.07%
大文字化:
|
ボリューム (24 時間):